INS and atherosclerosis: Therapeutic agents that improve insulin sensitivity, such as PPAR-γ agonists (e.g., pioglitazone), can help restore insulin signaling balance in VSMCs, reducing pathological proliferation and migration and potentially slowing atherosclerosis progression [160].